Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system

ConclusionsSimilar AE reporting between the two oxazolidinones was found. Considering limitations of pharmacovigilance, this hypothesis of comparable safety profile should be tested prospectively through dedicated real-world studies.PMID:34280062 | DOI:10.1080/14740338.2021.1956461

Source: Expert Opinion on Drug Safety - July 19, 2021 Category: Drugs & Pharmacology Authors: Milo Gatti Michele Fusaroli Emanuel Raschi Ugo Moretti Elisabetta Poluzzi Fabrizio De Ponti Source Type: research